Abstract
Neoadjuvant chemotherapy is able to convert unresectable breast tumors to resectable tumors and to provide more conservative surgery in some mastectomy candidates. Chemotherapy agents, including taxanes, which are recommended in the adjuvant setting, are also considered in the neoadjuvant setting.
A number of clinical studies with nab paclitaxel have also been performed in the neoadjuvant setting. Nab-paclitaxel demonstrated antitumor activity and an acceptable safety profile in the neoadjuvant treatment of breast cancer.
In some clinical trials, nab-paclitaxel was more effective than paclitaxel. Ongoing and future trials will further evaluate preoperative nab-paclitaxel in breast cancer, including in combination with many novel immunological targeted therapies.